Soranib 200 mg ( Sorafenib ) 30?film-coated tablets

Therapeutic indications:

Hepatocellular carcinoma

Soranib is indicated for the treatment of hepatocellular carcinoma.

Renal cell carcinoma

Soranib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Differentiated thyroid carcinoma

Soranib is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H?rthle cell) thyroid carcinoma, refractory to radioactive iodine.